首页> 外文期刊>Clinical ophthalmology >Reversibility of retinal ischemia due to central retinal artery occlusion by hyperbaric oxygen
【24h】

Reversibility of retinal ischemia due to central retinal artery occlusion by hyperbaric oxygen

机译:高压氧阻塞视网膜中央动脉引起的视网膜缺血可逆性

获取原文
           

摘要

Purpose: Ischemic retinal damage can be reversed by hyperbaric oxygen therapy (HBOT) as long as irreversible infarction damage has not developed. However, the time window till irreversible damage develops is still unknown. The study aim was to evaluate the effect of HBOT and determine possible markers for irreversible retinal damage. Materials and methods: Retrospective analysis of 225 patients treated with HBOT for central retinal artery occlusion (CRAO) in 1999–2015. One hundred and twenty-eight patients fulfilled inclusion/exclusion criteria: age >18 years, symptoms <20 hours, and best-corrected visual acuity (BCVA) <0.5 logMAR. Results: Time delay from symptoms to treatment was 7.8±3.8 hours. The BCVA was significantly improved after HBOT, from 2.14±0.50 to 1.61±0.78 ( P <0.0001). The proportion of patients with clinically meaningful visual improvement was significantly higher in patients without cherry-red spot (CRS) compared to patients with CRS at presentation (86.0% vs 57.6%, P <0.0001). The percentage of patients with final BCVA better than 1.0 was also significantly higher in patients without CRS vs patients with CRS at presentation (61.0% vs 7.1%, P <0.0001). There was no correlation between CRS and the time from symptoms. HBOT was found to be safe, and only 5.5% of patients had minor, reversible, adverse events. Conclusion: HBOT is an effective treatment for non-arteritic CRAO as long as CRS has not formed. The fundus findings, rather than the time delay, should be used as a marker for irreversible damage.
机译:目的:只要尚未发生不可逆性梗塞损害,可通过高压氧疗法(HBOT)逆转缺血性视网膜损害。但是,直到不可逆转的损害发展的时间窗口仍然未知。研究目的是评估HBOT的作用并确定不可逆性视网膜损伤的可能标志物。材料和方法:回顾性分析1999–2015年225例接受HBOT治疗的视网膜中央动脉阻塞(CRAO)患者。 128位患者符合纳入/排除标准:年龄> 18岁,症状<20小时,最佳矫正视力(BCVA)<0.5 logMAR。结果:从症状到治疗的时间延迟为7.8±3.8小时。 HBOT后BCVA显着提高,从2.14±0.50提高到1.61±0.78(P <0.0001)。没有表现出樱桃红斑病(CRS)的患者与具有临床意义的视觉改善的患者比例比出现CRS的患者显着更高(86.0%vs 57.6%,P <0.0001)。最终BCVA高于1.0的患者在没有CRS的患者中也比有CRS的患者显着更高(61.0%对7.1%,P <0.0001)。 CRS与症状发作时间之间没有相关性。 HBOT被发现是安全的,只有5.5%的患者发生了轻微,可逆的不良事件。结论:只要没有形成CRS,HBOT是治疗非动脉CRAO的有效方法。眼底的发现,而不是时间的延迟,应该用作不可逆转损伤的标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号